Medicale Corp: Pre‑revenue shell with $0 cash, rising convertible debt and going‑concern risk

Medicale Corp. (PINK: MCLE)

Quick read - what's happening inside the company
Medicale remains a pre-revenue shell that has not commenced operations. Management is conserving cash and funding operations with short-term convertible notes. Magenta Acres, Inc. holds ~54% and controls board-level decisions. Internal controls are weak (single officer/director performs all finance duties). The company disclosed substantial doubt about its ability to continue as a going concern.

Key facts & statistics
* Cash and cash equivalents (June 30, 2025): $0
* Total assets (June 30, 2025): $0
* Total liabilities (June 30, 2025): $129,416
* Stockholders' deficit (June 30, 2025): $(129,416)
* Accumulated deficit: $(206,328)
* Working capital deficiency: $(29,439) (Current liabilities $29,439 vs Current assets $0)
* Current liabilities breakdown: Accounts payable and accrued liabilities $8,447; Accrued interest payable $8,992; Current liabilities from discontinued operations $12,000
* Non‑current convertible notes payable: $99,977 (total convertible notes $99,977)
* Shares issued and outstanding (latest practicable date Aug 11, 2025): 5,920,000
* Potentially anti‑dilutive convertible shares (June 30, 2025): 5,528,520
* Net loss - three months ended June 30, 2025: $(5,528) (vs $(10,461) prior year Q)
* Net loss - nine months ended June 30, 2025: $(30,483) (vs $(41,332) prior year YTD)
* Operating expenses - three months: $3,575 (Q‑over‑Q down 62%); nine months: $24,839 (YTD down 37%)
* Interest expense - three months: $1,953 (up vs $1,173); nine months: $5,485 (up vs $2,134)
* Cash flow - net cash used in operating activities (nine months): $(16,551); cash provided by financing activities (nine months): $16,392; net change in cash: $(159)

Positive aspects (income statement & other)
* Operating expenses and reported net loss declined materially vs prior year (three‑month and nine‑month comparisons).
* Management has been able to raise financing via convertible notes (net proceeds $16,392 in the nine months).
* No material legal proceedings disclosed and no off‑balance sheet arrangements reported.

Negative aspects (income statement & other)
* Zero cash balance at period end while current liabilities total $29,439 - immediate liquidity risk.
* Accumulated deficit $(206,328) and continuing quarterly losses (nine‑month loss $30,483).
* Interest expense increased (nine months $5,485 vs $2,134), adding cash/earnings strain.
* Heavy reliance on convertible debt (non‑current notes $99,977) that can dilute existing shareholders - potential 5.53M anti‑dilutive shares.
* Weak internal controls: sole officer/director performs and approves all accounting tasks - disclosure controls deemed not effective.
* Company has not commenced operations and management warns of substantial doubt about going concern.

What to watch next
* New financing or equity raises (cash is $0).
* Any conversion or repayment of the convertible notes (will affect dilution and liabilities).
* Remediation of internal control weaknesses and independent financial oversight.
* Progress toward commencing operations and any revenue generation.
* Changes in related‑party / majority‑owner support from Magenta Acres, Inc.

Bottom line: Medicale Corp. is a pre‑revenue public shell with no cash, growing convertible debt and material control weaknesses. Reduced operating expenses have lowered losses, but liquidity and going‑concern risk remain urgent issues.